Our company began as Nymirum. As protein drug discovery continued to exhaust low-hanging fruits, we founded Nymirum in 2009 to tackle a new and challenging frontier filled with untapped therapeutic potential: targeting RNA with small molecules. We were focused on solving the some of the biggest hurdles in this modality. Namely, how to address the highly dynamic nature of RNA to enable structured-based drug discovery. The DART Platform was born. And now it has matured. Our evolution to Base4 is a natural progression to our company`s next era. The name is not only a nod to the four nucleotide bases of our RNA targets, but also a symbol of our stage of development and mentality for the exciting road ahead. On the Mount Everest climb, Camp IV, also known as South Col, is the final major camp before climbers begin the push to the summit. We have spent over a decade solving the platform challenges on this RNA journey and now is the time for the advancement to the peak.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Globally (various continents)
- Year Founded: